MiMedx price target lowered to $10 from $12 at Lake Street

Lake Street analyst Brooks O’Neil lowered the firm’s price target on MiMedx (MDXG) to $10 from $12 and keeps a Buy rating on the shares. While reducing its Wound segment estimates after CMS announced that the Medicare Administrative Contractors withdrew local coverage determinations, the firm thinks “patient investors have considerable upside potential as Surgical continues to grow and Wound stabilizes.”